Life sciences & healthcare legal cluster: Hub · Dawn raid · VBP · Hospital AR · Exclusive agency · HGR · Trial injury · CRO/CDMO · Device liability · Labeling · SaMD · Patent linkage · License · FDA WL · MDR/IVDR · Internet hospital · Trade secrets · Pharma ads · Device distribution · Sources · Checklist
Why foreign-invested parties get trapped
- Protocols designed at global HQ assume free secondary use and offshore bioinformatics.
- “Actual control” and collaboration structures with Chinese partners are mis-characterised in filings.
- CROs move residual samples or raw sequence data on legacy SOPs written for other countries.
- Databases and SaaS analytics create continuous outbound flows after a one-time approval mindset.
Core activity map (orientation)
Map every protocol step to: collection site, storage location, processing (including cloud), who can access identifiable vs coded data, whether materials or information leave mainland China, and which entity is the responsible Chinese party versus foreign collaborator. If you cannot draw this on one page, you are not filing-ready.
Outbound provision & “违规出境” risk narratives
Enforcement stories often feature unapproved outbound samples, sequence data, or collaborative research that effectively exports resource control. Penalties and operational consequences can include administrative sanctions, rectification orders, and programme interruption. Criminal exposure is fact-specific—treat wilful concealment as a different universe from good-faith process failure.
Foreign sponsors, CROs & “control” questions
Structures where a foreign entity directs collection strategy, owns primary analysis, or holds exclusive exploitation rights need careful characterisation under HGR practice. Do not assume a WFOE “solves HGR” without analysing what the WFOE actually controls versus global HQ systems.
When a trial is paused for HGR remediation
- Stop non-compliant outbound flows first; document the freeze.
- Inventory samples and data locations (including vendor and cloud).
- Engage counsel to design rectification and re-approval/filing strategy—do not “quietly re-label” shipments.
- Align communications to sites, ethics committees, and (if applicable) securities disclosure if you are listed.
- Re-open only with written pathway confirmation—not verbal comfort from a single vendor.
Biobank, residual samples & RWE programmes
Secondary research and real-world programmes amplify HGR + PIPL overlap. Build consent language, governance charters, and access logs for the secondary use you actually want—not the use marketing hopes for later. See also trial insurance/subject issues: subject injury & insurance.
Practical controls for global counsel
- HGR gate in every clinical and translational checklist before first-patient-in.
- Vendor due diligence clauses: audit rights, no silent offshore mirrors, breach notice in hours not weeks.
- Bioinformatics architecture: what must stay in-country vs what is truly anonymised under Chinese standards (anonymisation is not a slogan—see data roadmap).
- Training for PIs and study coordinators in Chinese, not only English protocol decks.
Related
Trial data integrity · CRO/CDMO disputes · Primary sources
FAQ · 高频检索问题
Chinese long-tail intents mapped to this guide (orientation only).
人类遗传资源违规出境怎么处罚？
外资药企是否必须自己做 HGR 主体？
生物样本库跨境如何合规？
Need sector counsel?
Map your issue to a specialty desk: Life sciences & healthcare · Devices & IVD · Clinical & health data · Product liability · Industry hub.
Find counsel
